Karen Bernstein - 26 Feb 2026 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Reporting relationship
Director
Issuer ticker
OVID
Reported as of
26 Feb 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
02 Mar 2026, 16:30:11 UTC
Prior SEC filing
18 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jeffrey Rona, Attorney-in-Fact

Key filing fact

Karen Bernstein filed Form 4 for Ovid Therapeutics Inc. (OVID) on 02 Mar 2026.

Key facts

  • This page summarizes Karen Bernstein's Form 4 filing for Ovid Therapeutics Inc. (OVID).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 02 Mar 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 18 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001654055 Primary reporting owner

Bernstein Karen

Relationship
Director
Address
C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, NEW YORK
Signature
/s/ Jeffrey Rona, Attorney-in-Fact
Signature date
02 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OVID transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+65,000
Change %
Price
$0.000000
Shares after
65,000
Date
26 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
65,000
Exercise price
$1.65
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .